Evaluating the impact of a community-based prostate cancer screening program.
324 Background: One out of eight men in the U.S. will be diagnosed with prostate cancer during his lifetime. Early detection, often by routine screening, allows for more options for treatment and an increased chance of survival. Barriers to screening exist and may contribute to prostate cancer disparities, particularly among Black males and those who lack regular access to health care. Community based screening programs may be an effective way to overcome barriers to prostate cancer screening. Methods: An urban, NCI-designated cancer center collaborated with community partners and a national prostate cancer advocacy organization to provide free screening to males in our catchment area. Community partners identified the location of the screening and promoted the event. Participants completed a survey about their personal and family history of prostate cancer. A mobile screening team within the cancer center conducted the screenings, consisting of prostate specific antigen (PSA) tests. All participants received a letter with their PSA test results; males with an abnormal result (> 3 ng/mL) also received a phone call. Survey data was analyzed with descriptive statistics and bivariate analyses (ANOVA). Results: Two hundred and eighty-nine (n=289) males were screened at a community screening event. The mean age of males screened was 57.3 (SD=11.2) and the majority identified as Black (N=253, 84.9%). The mean PSA test value was 1.82 (SD= 2.70); 14% of males had an abnormal PSA test result. Black males had the highest PSA values of among all men who were screened. Conclusions: Disparities in prostate cancer, particularly among Black males, warrant interventions like community-based prostate screening events that reduce barriers of cost and access, bringing screening to those who would most benefit. Mean PSA test results by patient characteristics. N Mean PSA Level Sum of Squares, DF Between Groups Within Groups F p Full Sample 298 1.82 Race/Ethnicity 3; 19.62 271; 1876.18 0.94 0.42 Black 246 1.85 Hispanic 18 0.80 White 9 1.48 Other 2 1.59 PSA in the last 3 years, # tests 3; 19.43 260; 1861.65 0.91 0.44 0 121 1.62 1-3 133 1.82 4-6 6 3.40 7+ 4 2.08 Family history of PCa, # of relatives 2; 54.09 287; 2051.72 3.78 0.024* 0 215 1.78 1 63 1.50 2+ 12 3.84 Family history of PCa genetic risk, # of relatives 2; 11.75 287; 2094.06 0.81 0.45 0 229 1.71 1 52 2.24 2+
Authors
- Nicola Cianci
- Suzanne Barron
- Herschel Knapp (ORCID: https://orcid.org/0000-0003-0964-2889)
- Katie Bradley
- Leonard G. Gomella (ORCID: https://orcid.org/0000-0002-9466-489X)
- Amy Leader (ORCID: https://orcid.org/0000-0002-9514-3631)
- Olivia Dahlgren
- Luis Robles (ORCID: https://orcid.org/0000-0002-8909-8520)
- Kristine Pham
- Oleksandr Kolesnikov
- Robert Giamboy
- Fatuma Doka
- Jordan DeHoratius
Institutions
- Thomas Jefferson University (US)
- Carleton College (US)
- Thomas Jefferson University Hospital (US)
- Sidney Kimmel Cancer Center (US)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2025-02-10
- DOI
- https://doi.org/10.1200/jco.2025.43.5_suppl.324
- Primary Topic
- Global Cancer Incidence and Screening
- Type
- article
- Field-Weighted Citation Impact
- 0.00